{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:38:32Z","timestamp":1789843112661,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072096"],"award-info":[{"award-number":["82072096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271545"],"award-info":[{"award-number":["82271545"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.psychres.2023.115138","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T20:35:37Z","timestamp":1677616537000},"page":"115138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics"],"prefix":"10.1016","volume":"322","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-3864","authenticated-orcid":false,"given":"Jingda","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiannan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2023.115138_bib0001","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.psychres.2023.115138_bib0002","first-page":"S261","article-title":"Effects of hormones on cognition in schizophrenic male patients\u2013preliminary results","volume":"27","author":"Bratek","year":"2015","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.psychres.2023.115138_bib0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/JCP.v65n0207","article-title":"Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study","volume":"65","author":"Cavallaro","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0004","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics","volume":"80","author":"Cernea","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.psychres.2023.115138_bib0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1046\/j.1440-1819.2003.01151.x","article-title":"Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial","volume":"57","author":"Chiu","year":"2003","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2023.115138_bib0006","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The economic burden of schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.psychres.2023.115138_bib0007","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/wps.20714","article-title":"Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial","volume":"19","author":"Correll","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2517-6161.1977.tb01600.x","article-title":"Maximum likelihood from incomplete data via the Em algorithm","volume":"39","author":"Dempster","year":"1977","journal-title":"J. R. Stat. Soc. Ser. B (Methodological)"},{"key":"10.1016\/j.psychres.2023.115138_bib0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jclinepi.2021.08.001","article-title":"Tutorial on directed acyclic graphs","volume":"142","author":"Digitale","year":"2022","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.psychres.2023.115138_bib0011","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.psychres.2019.02.017","article-title":"Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2\/3 receptor blockade - an exploratory study","volume":"274","author":"D\u00fcring","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2023.115138_bib0012","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fpsyt.2018.00781","article-title":"Bone status in obese, non-diabetic, antipsychotic-treated patients, and effects of the glucagon-like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density","volume":"9","author":"Eriksson","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0013","first-page":"97","article-title":"Prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine","volume":"30","author":"Fric","year":"2003","journal-title":"Psychiatr. Prax."},{"key":"10.1016\/j.psychres.2023.115138_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1741-7015-6-17","article-title":"Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study","volume":"6","author":"Ganguli","year":"2008","journal-title":"BMC Med."},{"key":"10.1016\/j.psychres.2023.115138_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2011.07.025","article-title":"Prolactin concentrations in newly diagnosed, antipsychotic-na\u00efve patients with nonaffective psychosis","volume":"134","author":"Garcia-Rizo","year":"2012","journal-title":"Schizophr. Res."},{"issue":"Suppl 1","key":"10.1016\/j.psychres.2023.115138_bib0016","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psychres.2023.115138_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41537-021-00170-3","article-title":"Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study","volume":"7","author":"Hoekstra","year":"2021","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.psychres.2023.115138_bib0018","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1471-244X-12-218","article-title":"Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study","volume":"12","author":"Hong","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0019","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2023.115138_bib0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"Hui","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0021","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/NDT.S306573","article-title":"Effect of switching to brexpiprazole on plasma homovanillic acid levels and antipsychotic-related side effects in patients with schizophrenia or schizoaffective disorder","volume":"17","author":"Ichinose","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2023.115138_bib0022","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2023.115138_bib0023","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial","volume":"7","author":"Johnsen","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0024","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","volume":"31","author":"Kinon","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psychres.2023.115138_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2011.143","article-title":"Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics","volume":"18","author":"Kishimoto","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0026","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006569.pub3","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2023.115138_bib0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejim.2016.01.015","article-title":"The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia","volume":"30","author":"Krysiak","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.psychres.2023.115138_bib0029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1440-1819.2011.02296.x","article-title":"Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients","volume":"66","author":"Lee","year":"2012","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2023.115138_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1819.2009.02032.x","article-title":"Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study","volume":"64","author":"Lee","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2023.115138_bib0031","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2023.115138_bib0032","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/JCP.0b013e3181bf613e","article-title":"Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics","volume":"29","author":"Lin","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2023.115138_bib0033","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","article-title":"Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0034","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.psychres.2023.115138_bib0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.psychres.2023.115138_bib0036","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.psychres.2023.115138_bib0037","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1034\/j.1600-0528.2002.00008.x","article-title":"Directed acyclic graphs (DAGs): an aid to assess confounding in dental research","volume":"30","author":"Merchant","year":"2002","journal-title":"Commun. Dent. Oral Epidemiol."},{"key":"10.1016\/j.psychres.2023.115138_bib0038","doi-asserted-by":"crossref","first-page":"e89428","DOI":"10.1371\/journal.pone.0089428","article-title":"Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis","volume":"9","author":"Montalvo","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.psychres.2023.115138_bib0039","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.psychres.2023.115138_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0041","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.12028ah1","article-title":"Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice","volume":"74","author":"Newcomer","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0042","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2015.2582","article-title":"Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment","volume":"73","author":"Nielsen","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0043","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(21)02142-5","article-title":"Preventing relapse in schizophrenia needs better evidence","volume":"399","author":"Ostuzzi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2023.115138_bib0044","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00044011-200828080-00001","article-title":"Practical issues with amisulpride in the management of patients with schizophrenia","volume":"28","author":"Pani","year":"2008","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.psychres.2023.115138_bib0046","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2006.07.006","article-title":"Amisulpride-induced hyperprolactinemia is reversible following discontinuation","volume":"31","author":"Paparrigopoulos","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0047","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0048","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-R\u00f6ssler","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2023.115138_bib0049","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-0028-1112134","article-title":"Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and\/or safety\/tolerability issues with risperidone: a randomized, multicentre, open-label study","volume":"42","author":"Ryckmans","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0050","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.psychres.2023.115138_bib0051","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2023.115138_bib0052","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0053","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0054","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","article-title":"Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study","volume":"64","author":"Takeuchi","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2023.115138_bib0056","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0b013e3181accfec","article-title":"Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study","volume":"29","author":"Takeuchi","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2023.115138_bib0057","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41386-021-01244-7","article-title":"Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers","volume":"47","author":"Toledo","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2023.115138_bib0058","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/NDT.S80925","article-title":"Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study","volume":"11","author":"Wani","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2023.115138_bib0059","doi-asserted-by":"crossref","first-page":"423","DOI":"10.9758\/cpn.2019.17.3.423","article-title":"Switching antipsychotics to blonanserin in patients with schizophrenia: an open-label, prospective, multicenter study","volume":"17","author":"Woo","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.psychres.2023.115138_bib0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2007.56-b","article-title":"Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial","volume":"299","author":"Wu","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.psychres.2023.115138_bib0061","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/1039856218810166","article-title":"Switch-associated adverse events: focus on olanzapine","volume":"26","author":"Xu","year":"2018","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.psychres.2023.115138_bib0062","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psychres.2017.01.036","article-title":"Factors associated with complete discontinuation of medication among patients with schizophrenia in the year after hospital discharge","volume":"250","author":"Zhou","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2023.115138_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.892477","article-title":"Metformin in the treatment of amisulpride-induced hyperprolactinemia: a clinical trial","volume":"15","author":"Zhu","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.psychres.2023.115138_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.681418","article-title":"Safety and efficacy of high-dose vitamin B6 as an adjunctive treatment for antipsychotic-induced hyperprolactinemia in male patients with treatment-resistant schizophrenia","volume":"12","author":"Zhuo","year":"2021","journal-title":"Front. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178123000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178123000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:59:50Z","timestamp":1759039190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178123000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":64,"alternative-id":["S0165178123000896"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2023.115138","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2023.115138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115138"}}